Maze Therapeutics executive exercises and sells shares

Maze Therapeutics, Inc. officer Harold Bernstein (President, R&D & CMO) exercised stock options and sold shares on August 13, 2026 under a Rule 10b5-1 trading plan adopted on September 29, 2025.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. officer Harold Bernstein (President, R&D & CMO) exercised stock options and sold shares on August 13, 2026 under a Rule 10b5-1 trading plan adopted on September 29, 2025. He exercised options for 16,142 shares of common stock at an exercise price of $10.42 per share, reducing that option position and leaving 176,803 options outstanding from this award. The resulting 16,142 common shares were then sold at a weighted average price of $27.6063 per share, in multiple trades between $27.17 and $28.00. The options vest over four years, with 1/4 vested on October 3, 2023 and the remainder in equal monthly installments, conditioned on continued service.

Insider Trade Summary 10b5-1

Exercise and Sale: 16,142 shares ($277K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Bernstein Harold

Role President, R&D & CMO

Sold 16,142 shs ($446K)

Approx. gross sale proceeds $446K

Approx. exercise cost $168K

Approx. pre-tax spread $277K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F3	16,142	$0.00	$0.00
Exercise	Common Stock F1	16,142	$10.42	$168K
Sale	Common Stock F1, F2	16,142	$27.6063	$446K

Holdings After Transaction: Stock Option (Right to Buy) — 176,803 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.17 to $28.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Key Figures

Options exercised: 16,142 shares Exercise price: $10.42 per share Shares sold: 16,142 shares +4 more

7 metrics

Options exercised 16,142 shares Stock options for Maze Therapeutics common stock exercised on August 13, 2026

Exercise price $10.42 per share Exercise price of stock options converted into common stock

Shares sold 16,142 shares Common stock sold on August 13, 2026 following option exercise

Weighted average sale price $27.6063 per share Weighted average price for shares sold, with trades from $27.17 to $28.00

Remaining options from award 176,803 shares Stock options reported as beneficially owned after the transaction

Option expiration date October 26, 2032 Expiration of the stock option from which shares were exercised

10b5-1 plan adoption date September 29, 2025 Date Harold Bernstein adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), beneficially owned, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

beneficially owned financial

"the reporting person beneficially owned 176,803 shares underlying the option"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

vesting financial

"The option vested as to 1/4th of the total award and thereafter vested"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MAZE executive Harold Bernstein report in this Form 4?

Harold Bernstein reported exercising 16,142 stock options at $10.42 per share and selling 16,142 common shares at a weighted average price of $27.6063 on August 13, 2026.

Was the MAZE Form 4 transaction by Harold Bernstein under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by Harold Bernstein on September 29, 2025, indicating they followed a pre-arranged schedule.

How many Maze Therapeutics (MAZE) options does Harold Bernstein retain after this exercise?

After exercising, Harold Bernstein holds 176,803 stock options from the reported award. These options relate to Maze Therapeutics common stock and continue to be subject to their original terms, including the stated expiration date of October 26, 2032.

At what prices were Harold Bernstein’s MAZE shares sold on August 13, 2026?

The 16,142 common shares were sold at a weighted average price of $27.6063 per share, in multiple trades with individual prices ranging from $27.17 to $28.00 per share, according to the filing footnote.

What are the key terms of Harold Bernstein’s MAZE stock option award?

The option has an exercise price of $10.42 per share, an expiration date of October 26, 2032, and vested 1/4 on October 3, 2023 with the remainder vesting in equal monthly installments contingent on continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 04:54 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bernstein Harold

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D & CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2026		M(1)		16,142	A	$10.42	16,142	D
Common Stock	08/13/2026		S(1)		16,142	D	$27.6063(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.42	08/13/2026		M(1)			16,142	(3)	10/26/2032	Common Stock	16,142	$0	176,803	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.17 to $28.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)